Long-Term Persistence of Robust Antibody and Cytotoxic T Cell Responses in Recovered Patients Infected with SARS Coronavirus
Open Access
- 20 December 2006
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 1 (1) , e24
- https://doi.org/10.1371/journal.pone.0000024
Abstract
Most of the individuals infected with SARS coronavirus (SARS-CoV) spontaneously recovered without clinical intervention. However, the immunological correlates associated with patients' recovery are currently unknown. In this report, we have sequentially monitored 30 recovered patients over a two-year period to characterize temporal changes in SARS-CoV-specific antibody responses as well as cytotoxic T cell (CTL) responses. We have found persistence of robust antibody and CTL responses in all of the study subjects throughout the study period, with a moderate decline one year after the onset of symptoms. We have also identified two potential major CTL epitopes in N proteins based on ELISPOT analysis of pooled peptides. However, despite the potent immune responses and clinical recovery, peripheral lymphocyte counts in the recovered patients have not yet been restored to normal levels. In summary, our study has, for the first time, characterized the temporal and dynamic changes of humoral and CTL responses in the natural history of SARS-recovered individuals, and strongly supports the notion that high and sustainable levels of immune responses correlate strongly with the disease outcome. Our findings have direct implications for future design and development of effective therapeutic agents and vaccines against SARS-CoV infection.Keywords
This publication has 17 references indexed in Scilit:
- Antibody responses against SARS coronavirus are correlated with disease outcome of infected individualsJournal of Medical Virology, 2005
- Longitudinally Profiling Neutralizing Antibody Response to SARS Coronavirus with PseudotypesEmerging Infectious Diseases, 2005
- Antibody responses against SARS-coronavirus and its nucleocaspid in SARS patientsJournal of Clinical Virology, 2004
- Neutralizing Antibodies in Patients with Severe Acute Respiratory Syndrome-Associated Coronavirus InfectionThe Journal of Infectious Diseases, 2004
- Longitudinal Profile of Immunoglobulin G (IgG), IgM, and IgA Antibodies against the Severe Acute Respiratory Syndrome (SARS) Coronavirus Nucleocapsid Protein in Patients with Pneumonia Due to the SARS CoronavirusClinical and Vaccine Immunology, 2004
- Detection of Specific Antibodies to Severe Acute Respiratory Syndrome (SARS) Coronavirus Nucleocapsid Protein for Serodiagnosis of SARS Coronavirus PneumoniaJournal of Clinical Microbiology, 2004
- Significant Changes of Peripheral T Lymphocyte Subsets in Patients with Severe Acute Respiratory SyndromeThe Journal of Infectious Diseases, 2004
- A Cluster of Cases of Severe Acute Respiratory Syndrome in Hong KongNew England Journal of Medicine, 2003
- Identification of Severe Acute Respiratory Syndrome in CanadaNew England Journal of Medicine, 2003
- Coronavirus as a possible cause of severe acute respiratory syndromeThe Lancet, 2003